(Reuters) - U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma.
The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food and Drug Administration more than a month ahead of the expected March 8 decision date. It was approved for use by adults whose cancer cannot be treated with surgery or radiation or whose disease has spread to other parts of the body or returned following surgery.
Erivedge, known chemically as vismodegib, is the first drug to gain FDA approval for advanced basal cell carcinoma. Curis, which earned a $10 million milestone payment as a result of the approval, is entitled to royalty payments on sales of the drug... Read More